EXTON, Pa., Jan. 7 /PRNewswire-FirstCall/ -- Adolor Corporation announced that it will participate in the 22nd Annual JPMorgan Healthcare Conference, in San Francisco. The company’s presentation is scheduled for 1:30 p.m. (Pacific Time) on Tuesday, January 13, 2004. Bruce A. Peacock, president and chief executive officer, will present an overview of the company. A live and on-demand webcast of the presentation will be accessible on the company’s website, http://www.adolor.com/, in the “Investor Relations” section during the presentation, and archived audio of the presentation, including PowerPoint slides, will be available through January 20, 2004.
About Adolor Corporation
Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of prescription pain management products. Entereg(TM) (alvimopan), Adolor’s lead product candidate, is being developed to manage postoperative ileus, the gastrointestinal side effect which can affect millions of patients following many types of surgery. Entereg(TM) is also being developed to manage the bowel dysfunction which can negatively impact the quality of life for millions of patients using opioid analgesic products such as morphine for treating pain, as well as being developed for treating chronic constipation in patients not using opioids. Adolor is collaborating with GlaxoSmithKline for the development and commercialization of Entereg(TM). Adolor’s next product candidate is a sterile lidocaine patch in clinical development for treating postoperative incisional pain. Adolor also has a number of discovery research programs focused on the identification of novel compounds for the treatment of pain. By applying its knowledge and expertise in pain management, along with ingenuity, Adolor Corporation is seeking to make a positive difference for patients, caregivers, and the medical community.
This release, and oral statements made with respect to information contained in this release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management’s current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Such known risks and uncertainties relate to, among other factors: Adolor’s history of operating losses since inception and its need for additional funds to operate its business; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the risk that clinical trials for Adolor’s product candidates, including alvimopan, may not be successful; the risk that Adolor may not obtain regulatory approval for its products, whether due to adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of evaluating and interpreting data, or otherwise; Adolor’s reliance on its collaborators, including Glaxo Group Limited, in connection with the development and commercialization of Adolor’s product candidates; market acceptance of Adolor’s products, if regulatory approval is achieved; competition; and other risk factors detailed from time to time in reports filed by Adolor with the Securities and Exchange Commission.
Further information about these and other relevant risks and uncertainties may be found in Adolor’s filings with the SEC, including but not limited to Adolor’s Reports on Form 10-Q for the quarters ending September 30, 2003 filed October 29, 2003, June 30, 2003 filed August 7, 2003 and March 31, 2003 filed May 14, 2003; Adolor’s report on Form 10-K for the year ended December 31, 2002 filed March 18, 2003, and Adolor’s Registration Statement on Form S-3 filed October 27, 2003 File No. 333-107998. We urge you to carefully review and consider the disclosures found in our filings which are available in the SEC EDGAR database at http://www.sec.gov/ and from Adolor at http://www.adolor.com/. Given the uncertainties affecting pharmaceutical companies in the development stage, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Adolor undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise.
This press release is available on the website http://www.adolor.com/. Contact: Adolor Corporation Vox Medica (media) Lizanne Wentz Chris Getman (215) 925-9901 Corporate Communications Stern Investor Relations (investors) (484) 595-1500 Lilian Stern (212) 362-1200
Adolor Corporation
CONTACT: Lizanne Wentz, Corporate Communications, Adolor Corporation,+1-484-595-1500; or Vox Medica (media): Chris Getman, +1-215-925-9901, orStern Investor Relations (investors): Lilian Stern, +1-212-362-1200, both forAdolor
Web site: http://www.adolor.com/
